State Street’s Alto Neuroscience ANRO Stock Holding History

State Street’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.1M	Buy	685,945 +486,442	+244%	+$11.2M	﹤0.01%	2411
2026 Q1	$4.48M	Buy	199,503 +68,838	+53%	+$1.28M	﹤0.01%	3003
2025 Q4	$2.33M	Buy	130,665 +27,480	+27%	+$346K	﹤0.01%	3293
2025 Q3	$415K	Sell	103,185 -1,549	-1%	-$5.14K	﹤0.01%	3704
2025 Q2	$230K	Sell	104,734 -233,982	-69%	-$557K	﹤0.01%	3794
2025 Q1	$732K	Sell	338,716 -990	-0.3%	-$3.54K	﹤0.01%	3502
2024 Q4	$1.44M	Buy	339,706 +102,849	+43%	+$642K	﹤0.01%	3404
2024 Q3	$2.71M	Buy	236,857 +130,985	+124%	+$1.6M	﹤0.01%	3215
2024 Q2	$1.13M	Buy	105,872 +80,472	+317%	+$1.05M	﹤0.01%	3456
2024 Q1	$390K	Buy	+25,400	New	+$398K	﹤0.01%	3710

Other funds holding ANRO

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street's ANRO Position: Q2 2026 in Review

State Street increased its Alto Neuroscience (ANRO) stake by 244% in Q2 2026, buying an estimated $11.2M and bringing the position to 685,945 shares worth $18.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2411.

State Street first reported a position in ANRO in Q1 2024 and has held it in 10 quarters since. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

State Street held 685,945 shares of Alto Neuroscience worth $18.1M as of Q2 2026.
State Street bought 486,442 Alto Neuroscience shares in Q2 2026, an estimated $11.2M.
Alto Neuroscience made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2411 holding.
State Street first reported a position in Alto Neuroscience in Q1 2024 and has held it in 10 quarters since.
114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.